TAK-020   Click here for help

GtoPdb Ligand ID: 11730

Synonyms: compound 3 [PMID: 34448571] | TAK020
PDB Ligand
Compound class: Synthetic organic
Comment: TAK-020 is a covalent Bruton's tyrosine kinase (BTK) inhibitor [2]. The compound bonds to Cys481 in BTK's ATP binding site. It was designed for potential to treat haematologic malignancies and/or autoimmune diseases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 103.97
Molecular weight 351.13
XLogP 2.65
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2c1cccc2)c1n[nH]c(=O)[nH]1
Isomeric SMILES C(=O)(C=C)N1C[C@H](CC1)Oc1nc(cc2ccccc12)c1[nH]c(=O)[nH]n1
InChI InChI=1S/C18H17N5O3/c1-2-15(24)23-8-7-12(10-23)26-17-13-6-4-3-5-11(13)9-14(19-17)16-20-18(25)22-21-16/h2-6,9,12H,1,7-8,10H2,(H2,20,21,22,25)/t12-/m0/s1
InChI Key HIMUHMBGRATXMK-LBPRGKRZSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 1 safety and tolerability studies have been completed (September 2021).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02723201 TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants Phase 1 Interventional Takeda
NCT02413255 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers Phase 1 Interventional Takeda 1